Patryk Purta
Pulmonary Disease · Omaha, NENPI 1942798848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 34.9% of the total. 2025 is the largest year on record at $785, 6.3 times the $124 reported in 2021. That places this record below the midpoint for pulmonary disease clinicians in NE, where the typical reported total is $2,614.
Across 76 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$623
- Merck$159
- Grifols USA, LLC$134
- Biohaven Pharmaceuticals, Inc.$103
- Insmed, Inc.$83
- Boehringer Ingelheim$77
- plus $606 from 16 others
What the payments were for
- Food & beverage$1,76799%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $623 |
| Merck | 6 | $159 |
| Grifols USA, LLC | 5 | $134 |
| Biohaven Pharmaceuticals, Inc. | 1 | $103 |
| Insmed, Inc. | 4 | $83 |
| Boehringer Ingelheim | 4 | $77 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $72 |
| Amgen | 3 | $60 |
| Aurinia Pharma U.S., Inc. | 2 | $56 |
| UCB, Inc. | 2 | $56 |
| Sanofi | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| GSK | 3 | $43 |
| Viatris Specialty LLC | 2 | $30 |
| United Therapeutics Corporation | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$134
- BREZTRI$134
- FASENRA$134
- NURTEC ODT$103
How this compares
$1,786 in reported general payments places this provider in the 40th percentile of 81 pulmonary disease providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 16 | $103,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $28,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $10,661 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,678 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $5,669 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,090 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $317 |
| Prednisone | 26 | $177 |
| Montelukast Sodium | 16 | $124 |
| Azithromycin | 15 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $43 | $54,415102 claims |
| AstraZenecaSymbicort | $623 | $5,66924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.